EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study

Pauline Lemmens, Edouard Louis, Wouter Van Moerkercke, Lieven Pouillon, Michael Somers, Harald Peeters, Stijn Vanden Branden, Julie Busschaert, Filip Baert, Anneline Cremer, Philippe Potvin, Sophie Dewit und 10 weitere

Clinical Gastroenterology and Hepatology · 2024-01 · 22 (1) · 154-163.e3

DOI: 10.1016/j.cgh.2023.06.023 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-01. Verfasst von Pauline Lemmens und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Takeda Pharmaceutical Company Limited, Celltrion Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Several advanced therapies (biologic therapies and small molecules) have been approved for the treatment of moderate-to-severe ulcerative colitis. The registration trials for these agents typically excluded patients with isolated proctitis, leaving an evidence gap. We evaluated efficacy and safety of advanced therapies in patients with ulcerative proctitis (UP). METHODS: This multicenter retrospective cohort study included consecutive patients with active UP (Mayo endoscopy subscore of ≥2, rectal inflammation up to 15 cm) initiating advanced therapy, after failing conventional therapy. The primary end point was short-term steroid-free clinical remission (total Mayo score ≤2 with no individual subscore >1). In addition, drug persistence and relapse-free and colectomy-free survival were assessed. Both binary logistic and Cox regression analyses were performed. RESULTS: In total, 167 consecutive patients (52.0% female; median age 41.0 years; 82.0% bionaive) underwent 223 courses of therapy for UP (38 adalimumab, 14 golimumab, 54 infliximab, 9 ustekinumab, 99 vedolizumab, 9 tofacitinib). The primary end point was achieved with 36.3% of the treatment courses, and based on multivariate analysis, more commonly attained in bionaive patients (P = .001), patients treated with vedolizumab (P = .001), patients with moderate endoscopic disease activity (P = .002), and a body mass index

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHumansFemaleAdultMaleRetrospective StudiesBelgiumAdalimumabBiological TherapyTreatment Outcome

Stichwörter der Autor:innen

Advanced TherapyBiological TherapyProctitisSmall MoleculeUlcerative Colitis

Substanzen

Adalimumab

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
  • Department of Gastroenterology, CHU Liege and Liege University, Liege, Belgium.
  • Department of Hepatology and Gastroenterology, AZ Groeninge, Kortrijk, Belgium.
  • Department of Gastroenterology, Imelda Hospital, Bonheiden, Belgium.
  • Department of Gastroenterology, University Hospital Antwerp, Antwerp, Belgium.
  • Department of Gastroenterology, University Hospital Gent, Gent, Belgium.

Förderung

  • Takeda Pharmaceutical Company Limited
  • Celltrion Inc

Zitieren

APA

Lemmens, P., Louis, E., Van Moerkercke, W., Pouillon, L., Somers, M., Peeters, H., Vanden Branden, S., Busschaert, J., Baert, F., Cremer, A., Potvin, P., Dewit, S., Colard, A., Swinnen, J., Lambrecht, G., Claessens, C., Willandt, B., Dewint, P., Van Dyck, E., …, & Ferrante, M. (2024). Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study. Clinical Gastroenterology and Hepatology, 22(1), 154-163.e3. https://doi.org/10.1016/j.cgh.2023.06.023

Vancouver

Lemmens P, Louis E, Van Moerkercke W, Pouillon L, Somers M, Peeters H, et al. Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study. Clinical Gastroenterology and Hepatology. 2024;22(1):154-163.e3. doi:10.1016/j.cgh.2023.06.023

BibTeX
@article{Lemmens2024,
  author = {Lemmens, Pauline and Louis, Edouard and Van Moerkercke, Wouter and Pouillon, Lieven and Somers, Michael and Peeters, Harald and Vanden Branden, Stijn and Busschaert, Julie and Baert, Filip and Cremer, Anneline and Potvin, Philippe and Dewit, Sophie and Colard, Arnaud and Swinnen, Jo and Lambrecht, Guy and Claessens, Christophe and Willandt, Barbara and Dewint, Pieter and Van Dyck, Evi and Sabino, Joao and Vermeire, Séverine and Ferrante, Marc},
  title = {Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  volume = {22},
  number = {1},
  pages = {154--163.e3},
  doi = {10.1016/j.cgh.2023.06.023}
}
Kostenlos starten →